News

First report of a GIST patient responding to a BRAF inhibitor

First report of a GIST patient responding to a BRAF inhibitor. Dr. Gerald Falchook and colleagues at MD Anderson Cancer Center provided the first report of a GIST patient responding to a BRAF inhibitor. The BRAF gene is frequently mutated in melanoma and BRAF inhibitors provide one of the most important therapies available for melanoma patients

By |2019-09-20T12:57:43-04:00March 14th, 2013|News, Research|

LRG Urges Governor Christie to Restore Cancer Funding

The LRG is continually involved in advocacy efforts to increase government spending on cancer research. We have joined forces with other cancer agencies to once again urge Governor Chris Christie and the New Jersey Legislature to restore the $1 million budget appropriation

By |2019-09-20T12:58:11-04:00March 13th, 2013|Advocacy, News|

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By |2019-09-20T13:00:30-04:00February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

The LRG Pushes for New Ways to Research Rare Disease

Communication is a two-way street, but unfortunately that is not always the case when finding ways to research rare disease. Sharing of data by researchers does not happen as easily, or as often as you [...]

By |2019-09-20T13:01:02-04:00February 21st, 2013|Clinical Trials, News, Research|
Go to Top